T1	Participants 44 98	treatment on prolactin levels in children with autism.
T2	Participants 205 242	children and adolescents with autism.
T3	Participants 251 300	Patients with autism (N = 101, 5-17 years of age)
T4	Participants 366 424	63 then took part in a 4-month open-label follow-up phase.
T5	Participants 1422 1443	children with autism.
T6	Participants 1587 1611	children and adolescents
